— Know what they know.
Not Investment Advice

DNA NYSE

Ginkgo Bioworks Holdings, Inc.
1W: +2.8% 1M: -4.4% 3M: -12.5% YTD: -7.2% 1Y: +1.0% 3Y: -83.9% 5Y: -98.0%
$8.41
+0.33 (+4.08%)
 
Weekly Expected Move ±14.7%
$5 $7 $8 $9 $10
NYSE · Healthcare · Biotechnology · Alpha Radar Sell · Power 38 · $549.4M mcap · 48M float · 2.63% daily turnover · Short 60% of daily vol

Cash Flow Trends

Operating Cash Flow
-$171M +46.5% ▲
Capital Expenditures
$8M +87.7% ▲
5Y CAGR: -33.2%
Free Cash Flow
-$179M +53.2% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$393M -2.4% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$1.8B-$2.1B-$893M-$547M-$313M
Depreciation & Amort.$29M$43M$72M$63M$59M
Stock-Based Comp.$1.6B$1.9B$230M$112M$82M
Change in Working Capital-$62M-$37M$30M-$90M-$44M
Other Non-Cash Items-$21M-$67M$267M$143M$47M
Operating Cash Flow-$254M-$252M-$296M-$320M-$171M
— Investing Activities —
Capital Expenditures-$57M-$52M-$41M-$63M-$8M
Acquisitions (Net)-$12M$27M-$39M-$5M$0
Investment Purchases-$5M-$4M$0$0-$419M
Investment Sales$0$0$0$5M$185M
Other Investing$304K-$38M-$1M$1M$624K
Investing Cash Flow-$73M-$67M-$81M-$62M-$240M
— Financing Activities —
Net Debt Issuance-$1M-$1M-$1M-$897K-$354K
Stock Repurchased-$25M$0-$23K$0$0
Dividends Paid$0$0$0$0$0
Other Financing$1.6B-$3M-$1M-$922K$0
Financing Cash Flow$1.5B$95M-$3M-$2M$18M
Net Change in Cash$1.2B-$223M-$380M-$384M-$393M
Cash End of Period$1.6B$1.4B$990M$606M$174M
Free Cash Flow-$310M-$304M-$336M-$382M-$179M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms